RNA tumor viruses, DNA polymerases, and oncogenesis: some selective effects of rifampicin derivatives.
D000818:Animals; D000998:Antiviral Agents; D001354:Avian Leukosis Virus / Q000201:enzymology; D002415:Cats; D002454:Cell Differentiation; D002471:Cell Transformation, Neoplastic; D055598:Chemical Phenomena; D002621:Chemistry; D004254:DNA Nucleotidyltransferases / Q000037:antagonists & inhibitors / Q000302:isolation & purification* / Q000378:metabolism; D004261:DNA Replication; D004279:DNA, Viral; D006801:Humans; D007962:Leukocytes / Q000201:enzymology; D008208:Lymphatic System / Q000201:enzymology; D009369:Neoplasms; D009858:Oncogenic Viruses / Q000201:enzymology*; D012328:RNA Viruses / Q000201:enzymology*; D012334:RNA, Neoplasm; D012367:RNA, Viral; D012190:Retroviridae / Q000201:enzymology; D012293:Rifampin / Q000494:pharmacology*; D013997:Time Factors; D014762:Viral Interference
D000998:Antiviral Agents; D004279:DNA, Viral; D012334:RNA, Neoplasm; D012367:RNA, Viral; D004254:DNA Nucleotidyltransferases; D012293:Rifampin